Pacira BioSciences Announces Positive Topline Data from Phase 3 Study of EXPAREL as a Single-dose Femoral Nerve Block in the Adductor Canal for Total Knee Arthroplasty
September 07, 2022 07:00 ET
|
Pacira BioSciences
TAMPA, Fla., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today...
Pacira BioSciences Reports Preliminary Net Product Sales of $50.2 Million for July 2022
August 10, 2022 08:00 ET
|
Pacira BioSciences
-- EXPAREL average daily sales for July 2022 were 105 percent of July 2021 -- TAMPA, Fla., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its...
NFL Alumni Association and Pacira BioSciences Team Up to Educate Athletes and Communities About Non-Opioid Options to Manage Pain
August 09, 2022 07:30 ET
|
Pacira BioSciences
TAMPA, Fla. and MOUNT LAUREL, N.J., Aug. 09, 2022 (GLOBE NEWSWIRE) -- The National Football League Alumni Association (NFLA), the oldest, most well-known and well-respected retired player...
Pacira BioSciences Reports Second Quarter 2022 Financial Results
August 03, 2022 08:00 ET
|
Pacira BioSciences
-- Second quarter revenue of $169 million, increased 25% over prior year, demonstrating successful integration and synergies from Flexion acquisition –-- Strong topline performance delivers solid net...
Pacira BioSciences to Participate in Fireside Chat at the 2022 Wedbush PacGrow Healthcare Virtual Conference
August 02, 2022 08:00 ET
|
Pacira BioSciences
TAMPA, Fla., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the 2022 Wedbush PacGrow Healthcare...
Pacira to Report Second Quarter 2022 Financial Results on Wednesday August 3, 2022
July 27, 2022 08:00 ET
|
Pacira BioSciences
TAMPA, Fla., July 27, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its second quarter financial results before the open of the U.S. markets on...
Pacira BioSciences Reports Preliminary Second Quarter 2022 Revenue of $169.4 Million
July 14, 2022 07:30 ET
|
Pacira BioSciences
TAMPA, Fla., July 14, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today...
National Safety Council and Pacira BioSciences Partner to Launch an Employee-Based Program Focused on Opioid Use and Misuse
June 16, 2022 08:00 ET
|
Pacira BioSciences
TAMPA, Fla. and ITASCA, Ill., June 16, 2022 (GLOBE NEWSWIRE) -- The National Safety Council, America’s leading nonprofit safety advocate, and Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry...
Pacira BioSciences Reports Preliminary Net Product Sales for EXPAREL and iovera° of $46.0 Million for May 2022
June 14, 2022 08:00 ET
|
Pacira BioSciences
TAMPA, Fla., June 14, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today...
Pacira BioSciences to Participate in Fireside Chat at the Jefferies Healthcare Conference
June 02, 2022 08:00 ET
|
Pacira BioSciences
TAMPA, Fla., June 02, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the Jefferies Healthcare Conference...